How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,635 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (IPG478)

, with a view to providing data about cure and about recurrence rates, compared with other forms of treatment.’ Some minor changes were also made to the rest of the document after consultation. Description Basal cell carcinoma (BCC) is the most common type of skin cancer in the UK. It is generally a slow-growing, locally invasive epidermal skin tumour that rarely spreads to other parts of the body. Although it is not usually life-threatening, the tumour can cause extensive tissue destruction (...) if it is not treated. Squamous cell carcinoma (SCC) is the second most common type of skin cancer in the UK. It may spread into local lymph nodes and metastasise to other parts of the body. Current treatments for BCC and SCC include surgical excision and radiotherapy, and less commonly curettage, cryotherapy and chemotherapy. The OPCS-4 codes for Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma are: The relevant procurement/delivery codes in categories X70-X72 (depending

2014 National Institute for Health and Clinical Excellence - Interventional Procedures

22. A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies

, Testicular cancer, and Stage III rectal cancer. Any active malignancy within 3 years prior, except: Adequately treated basal cell or squamous cell skin cancer, or early stage cancers (carcinoma in situ or stage 1) treated with curative intent. Any uncontrolled intercurrent illness, including but not limited to: Symptomatic congestive heart failure, Unstable angina pectoris or coronary angioplasty or stenting within 6 months prior to enrollment, Cardiac arrhythmia, Psychiatric illness or social situations (...) -institution, single arm, open label, window of opportunity clinical trial that will act as a Master Protocol with a primary objective to assess pharmacodynamic effects of the novel study drugs in subjects with resectable solid tumor malignancies. Each Sub-protocol conducted under the Master Protocol will evaluate different novel therapeutic agent(s). Estimated enrollment is 15 subjects per Sub-Protocol. Condition or disease Intervention/treatment Phase Solid Tumor Drug: Epacadostat Phase 1 Detailed

2018 Clinical Trials

23. Classification of the clinical images for benign and malignant cutaneous tumors using a deep learning algorithm. Full Text available with Trip Pro

Classification of the clinical images for benign and malignant cutaneous tumors using a deep learning algorithm. We tested the use of a deep learning algorithm to classify the clinical images of 12 skin diseases-basal cell carcinoma, squamous cell carcinoma, intraepithelial carcinoma, actinic keratosis, seborrheic keratosis, malignant melanoma, melanocytic nevus, lentigo, pyogenic granuloma, hemangioma, dermatofibroma, and wart. The convolutional neural network (Microsoft ResNet-152 model (...) ; Microsoft Research Asia, Beijing, China) was fine-tuned with images from the training portion of the Asan dataset, MED-NODE dataset, and atlas site images (19,398 images in total). The trained model was validated with the testing portion of the Asan, Hallym and Edinburgh datasets. With the Asan dataset, the area under the curve for the diagnosis of basal cell carcinoma, squamous cell carcinoma, intraepithelial carcinoma, and melanoma was 0.96 ± 0.01, 0.83 ± 0.01, 0.82 ± 0.02, and 0.96 ± 0.00

2018 Journal of Investigative Dermatology

24. Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence

Gastroesophageal Junction Adenocarcinoma Clinical Stage III Esophageal Adenocarcinoma Clinical Stage III Esophageal Squamous Cell Carcinoma Clinical Stage III Gastric Cancer Clinical Stage III Gastroesophageal Junction Adenocarcinoma Distal Esophagus Squamous Cell Carcinoma Esophageal Carcinoma Estrogen Receptor Negative HER2/Neu Negative Limited Stage Small Cell Lung Carcinoma Malignant Solid Neoplasm Non-Small Cell Lung Carcinoma Pancreatic Adenocarcinoma Pathologic Stage II Esophageal Adenocarcinoma (...) Small Cell Lung Carcinoma Triple Negative Breast Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms by Site Breast Diseases Skin Diseases Respiratory Tract Neoplasms Thoracic Neoplasms Lung Diseases Respiratory Tract Diseases Neoplasms, Squamous Cell Digestive System Neoplasms Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases Endocrine System Diseases Gastrointestinal Neoplasms

2018 Clinical Trials

25. Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)

treated with marrow-suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated. Patients with a history of a different malignancy are ineligible except for the following circumstances: if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy; patients with treated cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin (...) (months). The median overall survival for GBM patients is 12-14 months from the time of diagnosis; therefore the development of new therapeutic options is imperative. HU has been used to treat hematological diseases and solid tumors (such as melanoma, ovarian, squamous cell carcinoma, head and neck carcinoma and brain tumors) in combination with other anti-cancer agents, but never with TMZ. If found safe, HU+TMZ, is easily translated to the clinic. Purpose: Phase I trial to identify the maximum

2018 Clinical Trials

26. A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

participating in this study, she should inform her treating physician immediately. Exclusion Criteria: Current or anticipated use of other investigational agents while participating in this study. Pregnant or breast feeding. Diagnosis of squamous cell cancer of the oropharynx Previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast), unless a complete remission was achieved at least 2 years prior (...) First Posted : June 18, 2018 Last Update Posted : July 24, 2018 See Sponsor: Joaquina Baranda Information provided by (Responsible Party): Joaquina Baranda, University of Kansas Medical Center Study Details Study Description Go to Brief Summary: This is a window-of-opportunity trial to determine if atorvastatin given for 1 to 4 weeks at a dose of 80 milligrams per day (mg/day) is sufficient to decrease the level of conformational mutant tumor protein 53 (p53) in malignant diseases (solid tumor

2018 Clinical Trials

27. A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

or disease Intervention/treatment Phase Stage III Cutaneous Melanoma Stage IV Cutaneous Melanoma Locally Advanced Melanoma Locally Advanced Solid Neoplasm Metastatic Head and Neck Squamous Cell Carcinoma Metastatic Malignant Solid Neoplasm Metastatic Melanoma Metastatic Urothelial Carcinoma Non-Small Cell Lung Carcinoma Stage IB Lung Cancer AJCC v7 Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 Stage III Lung Cancer AJCC v8 Stage III Ureter Cancer AJCC v8 Stage IIIA Lung Cancer (...) or metastatic solid tumor malignancy with one of the following tumor types: Urothelial carcinoma Melanoma Non-small cell lung cancer Head and neck squamous cell carcinoma MSI-high solid tumor, with MSI-high status defined by microsatellite instability testing by polymerase chain reaction (PCR), loss of mismatch repair proteins by immunohistochemistry (IHC), or Clinical Laboratory Improvement Act (CLIA)-approved next generation sequencing test. Measurable disease by RECIST 1.1 criteria. Dose Expansion only

2018 Clinical Trials

28. ΔNp63 in squamous cell carcinoma: Defining the oncogenic routes affecting epigenetic landscape and tumor microenvironment. Full Text available with Trip Pro

ΔNp63 in squamous cell carcinoma: Defining the oncogenic routes affecting epigenetic landscape and tumor microenvironment. Squamous cell carcinoma (SCC) is a treatment-refractory tumour, which arises from the epithelium of diverse anatomical sites, such as oesophagus, head and neck, lung, and skin. Accumulating evidence has revealed a number of genomic, clinical and molecular features commonly observed in SCC of distinct origins. Some of these genetic events culminate in fostering the activity (...) of ΔNp63, a potent oncogene which exerts its pro-tumorigenic effects by regulating specific transcriptional programs to sustain malignant cell proliferation and survival. In this review, we will describe the genetic and epigenetic determinants underlying ΔNp63 oncogenic activities in SCC, and discuss some relevant transcriptional effectors of ΔNp63, emphasizing their impact in modulating the crosstalk between tumour cells and tumour microenvironment (TME).Molecular Oncology (2019) © 2019 The Authors

2019 Molecular oncology

29. Usefulness of real-time elastography for diagnosing lymph node metastasis of skin cancer; does elastography potentially eliminate the need for sentinel lymph node biopsy in squamous cell carcinoma? (Abstract)

Usefulness of real-time elastography for diagnosing lymph node metastasis of skin cancer; does elastography potentially eliminate the need for sentinel lymph node biopsy in squamous cell carcinoma? The metastatic involvement of regional lymph nodes is the most important prognostic factor for overall survival of skin cancer patients. The sonographic technique of freehand real-time tissue elastography (RTE), which displays tissue rigidity as a color overlay of the tissue image, was developed.Our (...) purpose was to evaluate the benefit of RTE for detecting lymph node metastases of skin cancer noninvasively before operation.We first selected lymph nodes of skin cancer patients which had already been diagnosed by biopsy as being reactive or metastatic, and then retrospectively collected images of RTE and B-mode and color Doppler ultrasound on those lymph nodes performed preoperatively. Twenty-one lymph nodes from 12 patients with squamous cell carcinoma (SCC), 23 lymph nodes from 14 patients

2019 Journal of the European Academy of Dermatology and Venereology

30. Skin cancer precursor immunotherapy for squamous cell carcinoma prevention. Full Text available with Trip Pro

Skin cancer precursor immunotherapy for squamous cell carcinoma prevention. Topical calcipotriol plus 5-fluorouracil (5-FU) combination is an effective immunotherapy against actinic keratosis (AK), which is a precursor to squamous cell carcinoma (SCC). However, the long-term effectiveness of calcipotriol plus 5-FU treatment for SCC prevention is unknown.We performed a blinded prospective cohort study on participants of a randomized double-blind clinical trial in which a 4-day course of topical (...) calcipotriol plus 5-FU combination was compared to Vaseline plus 5-FU (control) for AK treatment. SCC and basal cell carcinoma (BCC) incidences were assessed at 1, 2, and 3 years after trial. Tissues were analyzed for calcipotriol plus 5-FU-induced T cell immunity in the skin.Calcipotriol plus 5-FU-induced tissue-resident memory T (Trm) cell formation in face and scalp skin associated with significantly higher erythema scores compared with control (P < 0.01). Importantly, more participants in the test

2019 JCI insight Controlled trial quality: uncertain

31. Cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma — Details

Cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma — Details Cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma — Details | CADTH.ca Find the information you need Cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma — Details Cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma — Details Project Number pCODR 10187 Brand Name Libtayo Generic Name Cemiplimab Strength 50mg/mL Tumour Type Skin & Melanoma Indication Cutaneous Squamous Cell Carcinoma Funding Request (...) For the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation. Review Status Under Review Pre Noc Submission No NOC Date April 10, 2019 Manufacturer Sanofi Genzyme Sponsor Sanofi Genzyme Submission Date July 9, 2019 Submission Deemed Complete July 30, 2019 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline ‡ July 23, 2019 Check-point meeting September 17, 2019 pERC Meeting

2019 CADTH - Pan Canadian Oncology Drug Review

32. Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V

? Catharina Brockhaus ? Gertrud Egger ? Thomas Kaiser ? Marco Knelangen ? Christopher Kunigkeit ? Miriam Luhnen ? Natalia Wolfram Keywords: nivolumab, carcinomasquamous cell, head and neck neoplasms, benefit assessment, NCT02105636 2 Due to legal data protection regulations, employees have the right not to be named. Extract of dossier assessment A17-24 Version 1.0 Nivolumab (squamous cell carcinoma of the head and neck) 30 August 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - iii (...) Version 1.0 Nivolumab (squamous cell carcinoma of the head and neck) 30 August 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - v - List of abbreviations Abbreviation Meaning ACT appropriate comparator therapy AE adverse event CTCAE Common Terminology Criteria for Adverse Events ECOG PS Eastern Cooperative Oncology Group Performance Status EORTC European Organisation for Research and Treatment of Cancer EQ-5D European Quality of Life-5 Dimensions 5-FU 5-fluorouracil G-BA Gemeinsamer

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

33. Alterations of the Human Skin N- and O-Glycome in Basal Cell Carcinoma and Squamous Cell Carcinoma Full Text available with Trip Pro

Alterations of the Human Skin N- and O-Glycome in Basal Cell Carcinoma and Squamous Cell Carcinoma The glycome of one of the largest and most exposed human organs, the skin, as well as glycan changes associated with non-melanoma skin cancers have not been studied in detail to date. Skin cancers such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are among the most frequent types of cancers with rising incidence rates in the aging population. We investigated the healthy human (...) skin N- and O-glycome and its changes associated with BCC and SCC. Matched patient samples were obtained from frozen biopsy and formalin-fixed paraffin-embedded tissue samples for glycomics analyses using two complementary glycomics approaches: porous graphitized carbon nano-liquid chromatography electro spray ionization tandem mass spectrometry and capillary gel electrophoresis with laser induced fluorescence detection. The human skin N-glycome is dominated by complex type N-glycans that exhibit

2018 Frontiers in oncology

34. Expression of oncogenic miR-17-92 and tumor suppressive miR-143-145 clusters in basal cell carcinoma and cutaneous squamous cell carcinoma. Full Text available with Trip Pro

Expression of oncogenic miR-17-92 and tumor suppressive miR-143-145 clusters in basal cell carcinoma and cutaneous squamous cell carcinoma. A variety of cancers are associated with the expression of the oncogenic miR-17-92 cluster (Oncomir-1) and tumor suppressor miR-143-5p/miR-145-5p. Epidermal skin cancer has not been investigated for the expression of miR-17-92 and miR-143-145 clusters, despite being extensively studied regarding global microRNA profiles. The goal of this study (...) was to investigate the expression and possible correlation of expression of miR17-92 and miR-143-145 cluster members in epidermal skin cancer.We evaluated punch biopsies from patients with cutaneous squamous cell carcinoma (cSCC, n=15) and basal cell carcinoma (BCC, n=16), along with control specimens from non-lesional epidermal skin (n=16). Expression levels of the miR17-92 cluster (including miR-17-5p, miR-17-3p, miR-18a-3p, miR-18a-5p, miR-19a-3p, miR-19a-5p, miR-19b-3p, miR-19b-1-5p, miR-20a-3p, miR-20a-5p

2017 Journal of dermatological science

35. Hydrochlorothiazide and Squamous Cell Skin Cancer: Remember when hypertension was easy?

research. www.acfp.ca November 25, 2019 (en français) Hydrochlorothiazide and Squamous Cell Skin Cancer: Remember when hypertension was easy? Clinical Question: Does hydrochlorothiazide increase the risk of squamous cell carcinoma (SCC) of the skin? Bottom Line: Observational data suggest an association between hydrochlorothiazide and the risk of SCC. Causation has not been proven. Risk appears to consistently increase with dose and duration (example: 5 years of use increases risk 3-4 times). Baseline (...) Hydrochlorothiazide and Squamous Cell Skin Cancer: Remember when hypertension was easy? 1 Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care

2019 Tools for Practice

36. Risk of basal cell carcinoma, squamous cell carcinoma, or melanoma skin cancers in users of antihypertensive medications compared to non-users

Risk of basal cell carcinoma, squamous cell carcinoma, or melanoma skin cancers in users of antihypertensive medications compared to non-users Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) ); sex (stratified per sex); duration of index ischemia (linear); stem cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models

2019 PROSPERO

37. The volatilome – investigation of volatile organic metabolites (VOM) as potential tumor markers in patients with head and neck squamous cell carcinoma (HNSCC) Full Text available with Trip Pro

factors, nutritional and disease status. As a result of pathological processes the individual body odor can be influenced by newly produced or altered compositions of the VOM. Until now, human VOM have been detected in various body media, such as on the skin, in the exhaled air as well as in body fluids such as saliva, mother's milk, sweat, blood and urine.In this retrospective case-control study urinary VOM of 53 therapy-naive patients with head and neck squamous cell carcinoma (HNSCC) and 82 healthy (...) The volatilome – investigation of volatile organic metabolites (VOM) as potential tumor markers in patients with head and neck squamous cell carcinoma (HNSCC) Different organisms such as bacteria, molds and humans produce and release a relative unknown class of metabolites which are responsible for the individual olfactory pattern. These volatile organic metabolites (VOM) represent a kind of biosignature that reflects the sum of all multifactorial influences, including genetics, environmental

2018 Journal of Otolaryngology - Head & Neck Surgery

38. An unusual location of squamous cell carcinoma and a rare cutaneous infection caused by serratia marcescens on the tumoral tissue: A case report. Full Text available with Trip Pro

An unusual location of squamous cell carcinoma and a rare cutaneous infection caused by serratia marcescens on the tumoral tissue: A case report. Serratia marcescens (S. marcescens) is an opportunistic pathogen of the Enterobacteriaceae family. Although S. marcescens is known to cause sepsis, meningitis, endocarditis, urinary system and ocular infections, skin infections are sporadic. Squamous cell carcinoma (SCC) is the most aggressive skin cancer type that is often located in the head (...) knowledge, there have not been any cases reported with S. marcescens causing cutaneous infections on SCC. Therefore, our report is the first case in the literature.According to the culture antibiogram, S. marcescens was ciprofloxacin sensitive. Consequently, 1000 mg/day ciprofloxacin was initiated for 14 days.Purulent exudate in skin cancers may be caused by the nature of carcinoma tissue as well as the colonization of opportunistic pathogen microorganisms as seen in our patient.Examination of the wound

2018 Medicine

39. miR-186 promotes tumor growth in cutaneous squamous cell carcinoma by inhibiting apoptotic protease activating factor-1 Full Text available with Trip Pro

miR-186 promotes tumor growth in cutaneous squamous cell carcinoma by inhibiting apoptotic protease activating factor-1 Cutaneous squamous cell carcinoma (cSCC) accounts for 20% of non-melanoma skin cancer worldwide. MicroRNAs (miRNAs or miRs) are a subtype of non-coding RNA associated with the progression of various types of human cancer. MiR-186 has been demonstrated to act as an oncogene in human tumors. However, the role of miR-186 in cSCC remains unclear. The expression of miR-186 (...) and apoptotic protease activating factor 1 (APAF1) was examined using reverse transcription-quantitative polymerase chain reaction, western blotting and immunofluorescence. The correlation between miR-186 and APAF1 was determined using a dual-luciferase assay. Mimics or inhibitors of miR-186 were transfected into A-431 cells to establish cell lines with overexpressed or knocked-down miR-186, respectively. EdU staining and colony formation assays were performed to detect cell proliferation. Transwell

2018 Experimental and therapeutic medicine

40. Guidelines of care for the management of cutaneous squamous cell carcinoma Full Text available with Trip Pro

of fluorescence-guided surgical excision of nonmelanotic cutaneous malignancies. J Otolaryngol . 2007 ; 36 : 148–155 | | | , x 47 Campoli, M., Brodland, D.G., and Zitelli, J. A prospective evaluation of the clinical, histologic, and therapeutic variables associated with incidental perineural invasion in cutaneous squamous cell carcinoma. J Am Acad Dermatol . 2014 ; 70 : 630–636 | | | | | , x 48 Lott, D.G., Manz, R., Koch, C., and Lorenz, R.R. Aggressive behavior of nonmelanotic skin cancers in solid organ (...) Subject Headings) terms used in various combinations in the literature search included carcinoma , basal cell carcinoma , squamous cell carcinoma , skin neoplasms , stage ( ing ), grade ( ing ), score ( ing ), biopsy , pathology , prognosis , signs and symptoms , risk factors , curettage , electrodesiccation , excision , incomplete , cryosurgery , Mohs ( micrographic ) surgery , topical , fluorouracil , imiquimod , laser , radiotherapy , radiation , photochemotherapy , phototherapy , metastasis

2018 American Academy of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>